Skip to content

SHPH

Shuttle Pharmaceuticals Holdings, Inc.

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US

$3.50
+0.57%
Ask drillr

Year over year

Reported trailing growth

Revenue
EBITDA
-2.5%
EBIT
-20.7%
EPS
Free cash flow
Operating cash flow

Forward estimates

Based on analyst estimates

Revenue
EBITDA
EPS

Three-year CAGR

Revenue
EBITDA
-46.0%
EBIT
-54.8%
Net income
-28.2%
EPS
+99.2%
Free cash flow
-29.4%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026